Skip to content

ESMO Congress 2026

October 23–27, 2026 · Madrid · 5018 items

← All topics

DELLPHI-305

★★★

87 people · 131 posts

Heat trend for this story

Heat now 1·Peak in the comparable set 3 (Oct 27 22:00)·Change over 24h in the comparable set –·Participants now 4

Participants counted4
01234
Heat over time
0123Oct27Oct28Oct28Oct28
Deep dive

Tarlatamab, a DLL3-targeting bispecific T-cell engager, has been approved (IMDELLTRA) for second-line small cell lung cancer [8]; the DeLLphi-303 phase 1b study showed sustained survival benefit with tarlatamab plus anti-PD-L1 as first-line maintenance [5], while DeLLphi-300 substudy and real-world data further characterized its safety profile including cytokine release syndrome [6][12]. Against this background, the phase 3 DeLLphi-305 trial was designed to evaluate tarlatamab combined with durvalumab as first-line maintenance after chemoimmunotherapy in extensive-stage SCLC (ES-SCLC).

At the ESMO 2026 Presidential Symposium (LBA3), Professor Jacob Sands of Dana-Farber presented the primary analysis of DeLLphi-305 [N5]. This open-label phase 3 trial enrolled 563 patients with ES-SCLC without progression after durvalumab plus platinum-etoposide, randomized to tarlatamab-durvalumab or durvalumab alone [OncoAlert, DrChoueiri]. At a median follow-up of 16 months, median overall survival (OS) was 21.1 vs 12.7 months, hazard ratio (HR) 0.42 (95% CI 0.32–0.54, P<0.001) [DrChoueiri, NEJM, GlopesMd]; median progression-free survival (PFS) was 7.4 vs 1.9 months, HR 0.34 [lungoncdoc]; 12-month OS rates were 79.4% vs 53.3% [GlopesMd], representing a 58% reduction in death risk [martinvars].

Main-site news reports align with on-site data. BioSpace and Chinese industry outlets confirm the same OS, PFS figures and 58% risk reduction, noting median follow-up of 16 months [N2][N3]; CFI daily logs show the trial topped discussion on October 24 (53 posters) and remained high on October 27 [N4][N1]; the New England Journal of Medicine concurrently published the full manuscript, specifying a prespecified interim analysis (data cutoff July 7, 2026) [7][NEJM].

The results push median OS in first-line maintenance for ES-SCLC to 21.1 months, an 8.4-month improvement over the current standard, hailed on-site as a "practice-changing" advance [DrChoueiri, Tony_Calles, martinvars]. However, real-world management of cytokine release syndrome, treatment cost, and quality of life require further observation [SuyogCancer, GlopesMd]; the reported data represent a prespecified interim analysis, with final analysis pending [7].

References
  1. 1.2551TIP Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer · ESMO 2026 2026
  2. 2.2614O 2614O · ESMO 2026 2026
  3. 3.2876RO TQB2102, a novel HER2 bispecific antibody-drug conjugate, combined with bemotrizumab with or without capecitabine as first-line therapy for HER2-positive advanced gastric/gastroesophageal junction cancer: A phase II stud… · ESMO 2026 2026
  4. 4.2954TIP CLARITY-Gastric 02: A randomised phase 3 study of sonesitatug vedotin (Sone-Ve) and capecitabine with or without rilvegostomig in Claudin18.2 positive (CLDN18.2+) advanced or metastatic gastric, gastroesophageal junction… · ESMO 2026 2026
  5. 5.3821P Sustained survival with extended follow-up of tarlatamab plus anti-PD-L1 as first-line maintenance (1LM) after chemoimmunotherapy for extensive-stage small cell lung cancer (ES-SCLC): DeLLphi-303 phase 1b study · ESMO 2026 2026
  6. 6.3848P Cytokine release syndrome in patients receiving tarlatamab for extensive-stage small cell lung cancer: A real-world analysis · ESMO 2026 2026
  7. 7.Tarlatamab-Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer · N Engl J Med 2026
  8. 8.Antibodies to watch in 2025 · MAbs 2025
  9. 9.DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy · Mol Cancer 2024
  10. 10.Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities · Signal Transduct Target Ther 2024
  11. 11.Current and future therapies for small cell lung carcinoma · J Hematol Oncol 2025
  12. 12.Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy · ESMO Open 2025
Floor
  1. Dr Rishabh Jain

    ESMO 2026 | TOP 10 LUNG CANCER TRIALS TO WATCH!

    引用@

    🚨 ESMO 2026: 15 Trials That Could Change Oncology Practice! From personalized cancer vaccines and bispecific antibodies to next-generation ADCs, major results are coming. 🔥 My Top 15 to Watch: 1. INTerpath-001 | Melanoma 2. SAFFRON | EGFR+ NSCLC 3. Krascendo 1 | KRAS G12C NSCLC 4. DeLLphi-305 | ES-SCLC 5. HARMONi-GI1 | Biliary 6. VOLGA | Bladder 7. DASL-HiCaP | Prostate 8. NATALEE | Breast 9. TRIO-US B-12 TALENT | Breast 10. ENERGIZE | Bladder 11. CLARITY-Gastric 01 | Gastric 12. KEYNOTE-C93 | Endometrial 13. KEYNOTE-B49 | Breast 14. LITESPARK-011 | RCC 15. SigVie-002 | NSCLC 📊 The big question: Which trials will deliver meaningful survival benefits and redefine standards of care? Not every positive trial is practice-changing. 👨‍⚕️ Oncologists, which trial are you watching most closely? #ESMO26 #Oncology #CancerResearch @ASCO @oncoalert @myesmo @esmo_open

    ★★★Same topic DELLPHI-305 · 87 peopleSAFFRONKRASCENDOOPTITROP-LUNG06OPTITROP-LUNG04DELLPHI-304ASTRIDEtarlatamabdurvalumab6934 views88 likes27 reposts0 replies
  23. Dra. María Natalia Gandur Quiroga

    🚨 #ESMO26 Lung Cancer: the 10 studies that best capture where the field is moving

    引用@

    🚨 #ESMO26 Lung Cancer: Top Ten by @OncoAlert 🫁 The abstracts our faculty picked as must-know from Madrid 👇 1️⃣ DeLLphi-305 (LBA3): tarlatamab + durvalumab, 1L maintenance in ES-SCLC 2️⃣ Krascendo 1 (LBA5): divarasib vs sotorasib/adagrasib in KRAS G12C NSCLC 3️⃣ SAFFRON (LBA6): osimertinib + savolitinib in EGFRm MET+ NSCLC post-osimertinib 4️⃣ OptiTROP-Lung04 (LBA67): final OS, sac-TMT vs chemo after EGFR-TKI 5️⃣ OptiTROP-Lung06 (LBA66): sac-TMT + pembro, 1L PD-L1-negative non-squamous NSCLC 6️⃣ PERSEE (2614O): pembro ± chemo, 1L PD-L1 ≥50% 7️⃣ SANOVO (LBA69): savolitinib + osimertinib, 1L EGFRm MET-overexpressed NSCLC 8️⃣ IFCT-2103 DIAL (2618RO): continue pembro vs observation at 6 months 9️⃣ PANKU-Lung01 (LBA71): iza-bren after third-generation EGFR TKI 🔟 SARON (2613O): consolidation radiotherapy in oligometastatic NSCLC #lcsm #OncoAlert #MedTwitter Pinging our OncoAlert Lung Cancer Faculty @christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @jillfeldman4, @UOzkerim, @DrMirallas, @MartinReck2 , @bmassutis @UmbertoMalapel1 , @CharuAggarwalMD @peters_solange, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @VanitaNoronha, @ChristianRolfo @Tony_Calles @s_couraud @marinagarassino @g_mountzios @BairdAM @barlesi @JFreemanDaily @Piuchagarrido @LeciaSequist @bensolomon1 @VanitaNoronha +@alexdrilon @JordiRemon @caliraf @JulienMazieres @TerriConneran

    Same topic DELLPHI-305 · 87 peopleKRASCENDOSAFFRONOPTITROP-LUNG04OPTITROP-LUNG06SANOVOtarlatamabdurvalumabdivarasib407 views4 likes3 reposts0 replies
  25. Dr Jérôme BARRIERE, MD.

    🫁 Une avancée majeure dans le cancer bronchique à petites cellules !

    引用@

    Presented at #ESMO26: In a prespecified interim analysis of a phase 3 trial involving patients with extensive-stage SCLC, the median overall survival was 21.1 months with tarlatamab–durvalumab maintenance therapy and 12.7 months with durvalumab alone. Full DeLLphi-305 trial results: https://nej.md/4iveIgW @myESMO

    Same topic DELLPHI-305 · 87 peopletarlatamabdurvalumabDLL373 views5 likes1 repost0 replies
  28. Masahiro TORASAWA, MD. PhD.

    #ESMO26 LBA3

    引用@

    1/4 🔥 #ESMO26 Lung Cancer Presidential Highlights 🇪🇸 Madrid | October 24–25, 2026 Three major Phase 3 lung cancer LBAs, each with potential to reshape treatment paradigms: 🎙️ LBA3 | DeLLphi-305 🎙️ LBA5 | KRASCENDO 1 🎙️ LBA6 | SAFFRON Three Phase 3 readouts to watch closely at #ESMO26 👀 @myESMO @OncoAlert @Larvol

    Same topic DELLPHI-305 · 87 peopleLBA3tarlatamabdurvalumab335 views6 likes0 reposts1 reply
CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.